Abstract Purpose This study aimed to reveal Danggui Buxue Decoction (DBD) candidate targets and mechanisms in the treatment of metastatic colon cancer (MCC), using network pharmacology-based analyses and experimental validation. Methods Traditional Chinese Medicine Systems Pharmacology (TCMSP) database query and text mining were used to screen active compounds in DBD, and the Swiss target prediction platform was applied to predict compound-related target proteins. Targets likely associated with MCC were determined using GeneCards and OMIM databases. Targets common to DBD and MCC were obtained from the Venn platform; subsequently, Cytoscape was used to construct drug-compound-target-disease and protein-protein interaction networks. The hub gene was determined by R, while GO and KEGG enrichment analyses were performed on common targets to elucidate biological processes and signaling pathways involved in DBD against MCC. Finally, the metastatic colon cancer mouse model was used to detect the levels of expression of protein Bax, Bcl2, Caspase3, and Cleaved caspase3 by Western blot. Results A total of 28 active compounds and 61 common targets were predicted. The main compounds were quercetin, hederagenin, jaranol, methylnissolin, formononetin, calycosin, kaempferol, 3.9-di-O-methylnissolin, 24-propylcholesterol, and 7-O-methylisomucronulatol, present in Astragalus membranaceus (Huangqi, HQ). In addition, beta-sitosterol, ferulic acid, and stigmasterol, present in Angelica sinensis (Danggui, DG), were detected. JUN, PTSG2, EGFR, ESR1and, CASP3 genes were the top 5 hub genes in the PPI network. GO and KEGG enrichment analyses indicated that apoptosis played a major role in the biological processes and signaling pathways involved. Moreover, the in vivo experiment revealed that DBD inhibited MCC by up-regulating the expression of Bax, Caspase3, and Cleaved caspase3, and by down-regulating the expression of Bcl2. Conclusion This study revealed candidate DBD targets and mechanisms in the treatment of MCC, using network pharmacology-based analyses and experimental validation. The present findings provide a reference for tumor treatment during the perioperative period. Keywords: Danggui Buxue Decoction, network pharmacology, primary tumor, metastatic tumor, perioperative period Introduction Colon cancer is the third most frequently diagnosed malignant tumor and the second leading cause of cancer-related deaths worldwide.[36]1 Surgery as the primary treatment for malignant tumors has significantly improved the prognosis and quality of life of cancer patients. The risk of metastatic tumor development following surgery remains the major factor associated with the limited efficacy of the operation. Evidence suggests that the perioperative period and excision of the primary tumor can promote the development of metastases, which is the main cause of cancer-related mortality.[37]2–4 The perioperative period of approximately 5–7 days before and 7–12 days after tumor excision is pivotal in determining long-term cancer outcomes and the risk of postoperative metastatic disease. Although surgical removal of the primary tumor can reduce the tumor burden, it can also facilitate the development of metastases through numerous mechanisms, for example, cell immunosuppression and stress response,[38]5–7 tumor angiogenic switch imbalance,[39]8,[40]9 tumor cell dissemination through the blood and lymphatic systems, and the release of growth factors.[41]10,[42]11 These processes work synergistically during the perioperative period, significantly increasing the risk of metastases. This evidence suggests that the perioperative period may be used to suppress metastatic progression and improve oncological outcomes. However, conventional chemoradiotherapy cannot be used during this period, given its suppressive effects on the immune system and tissue healing.[43]4 Thus, there is a need for an alternative approach. Reinforcing qi and nourishing the blood are among the approaches used in conventional traditional Chinese medicine (TCM) to correct blood loss resulting from operation. Danggui Buxue Decoction (DBD) is a classic Chinese prescription first described in “NeiwaishangBianhuoLun” written by Dong-yuan Li in China (Jin Dynasty, CE 1247).[44]12 It includes the root of Astragalus membranaceus (Fisch.) Bunge. (Huangqi, HQ) and the root of Angelica sinensis (Oliv.) Diels. (Danggui, DG) at the ratio of 5:1 and is used for treating qi and the blood deficiency syndrome.[45]13 Studies have shown that DBD can attenuate apoptosis of hematopoietic stem cells in the mouse model of aplastic anemia,[46]14 improve bone marrow suppression induced by cyclophosphamide by promoting the synthesis and secretion of hematopoietic growth factors and the proliferation of hematopoietic progenitor cells,[47]15 and promote dermal wound healing by reducing the level of inflammatory response.[48]16 In addition, DBD can promote immune response by increasing the levels of lymphocytes, macrophages, and interleukin-2.[49]17 This decoction is widely used in clinical practice due to its therapeutic effects. Recent pharmacological studies have shown the evidence of anti-tumor effects of DBD; in fact, the use of DBD for NSCLC patients at an early post-operational stage has been associated with alleviated impairment and accelerated recovery of patients’ immune function.[50]18 Different concentrations of DBD may inhibit the proliferation of endothelial cells co-cultured with A549 lung cancer cells.[51]19 Moreover, DBD has been shown to significantly inhibit the formation of lung metastases in the Lewis lung cancer mouse model. However, little is known about the molecular mechanisms of DBD against MCC. Network pharmacology uses systems biology theory to predict potential mechanism of drug action in the treatment of diseases through compound-target-disease interaction network and bioinformatics analysis,[52]20 which are consistent with the holistic perspective of TCM. This study aimed to explore the anti-tumor effects of DBD on MCC during the perioperative period. Network pharmacology and bioinformatics analyses were used to predict candidate compounds and mechanisms of DBD in the treatment of MCC. In addition, an in vivo experiment was conducted to detect the levels of expression of apoptosis-related protein Bcl2, Bax, Caspase3 (Cas3), and Cleaved caspase3 (C-cas3) to provide a reference for the application of tonic therapy of tumor treatment in the perioperative period. Materials and Methods Drug, Reagents and Cell Line A. membranaceus (Inner Mongolia Autonomous Region, China, batch number 191,210,600) and A. sinensis (Gansu province, China, batch number 200,501) were purchased from the First Affiliated Hospital of Chongqing Medical University (Chongqing, China). Primary antibodies against Bcl2 (AF6139), Bax (AF0120), C-cas3 (AF7022) and β-actin (AF7018) were purchased from Affinity (Cincinnati, USA). Cas3 (27,525); and secondary antibodies goat anti-rabbit Ig G and goat anti-mouse lgG were purchased from Signalway Antibody (College Park, Maryland, USA). Mouse colon cancer cell line CT26 (CL-0071) was purchased from Procell Life Science&Technology Co., Ltd (Wuhan City, China) and cultured in RPMI 1640 (BI, Kibbutz Beit Haemek, Israel), supplemented with 10% fetal bovine serum (Lot1922693, BI, Kibbutz Beit Haemek, Israel) and 1% penicillin/streptomycin (Beyotime, shanghai, China). All cultures were maintained in a humidified environment with 5% CO[2] at 37°C. Network Pharmacology Analyses Active Compounds and Protein Targets Identification of DBD Data on DBD active compounds were collected from the TCMSP database ([53]http://lsp.nwsuaf.edu.cn), using the ADME filter method whose main parameters included oral bioavailability (OB) and drug-likeness (DL). OB of ≥30% and DL of ≥0.18 were the threshold values for ADME evaluation systems. Compounds such as astragalus polysaccharide, astragaloside, astragaloside III, astragaloside IV, alpha-Angelica lactone and ferulic acid, which exhibit anti-tumor effect, were identified as potential compounds in DBD via text mining. The CAS number of each compound was uploaded to the Pubchem platform ([54]https://pubchem.ncbi.nlm.nih.gov/) to obtain its 2D structure; subsequently, the Swiss Target Prediction platform ([55]http://www.swisstargetprediction.ch/) and TCMSP database were used to identify compounds-related targets; at this stage, zero probability and repeated targets were removed. The human gene symbol corresponding to the protein target name was standardized using the Uniprot database ([56]https://www.uniprot.org/). MCC-Related Targets Prediction Target genes associated with MCC were acquired from GeneCards ([57]https://www.genecards.org/) and OMIM ([58]https://omim.org/) databases. The targets common in DBD and MCC were identified by the Venn platform ([59]http://bioinformatics.psb.ugent.be/webtools/Venn/) and included in further analysis. Network Construction Data on the compounds and common targets were imported into Cytoscape 3.7.2 to construct the drug-compound-target-disease interaction network. The topological parameters of each node, including the degree centrality (DC), betweenness centrality (BC) and closeness of centrality (CC) were evaluated by NetworkAnalyzer plug-in for Cytoscape. String 11.0 ([60]https://string-db.org/) was used to determine protein-protein interactions, given the human species, medium confidence score of 0.4, and interaction data derived from literature mining, experiments, and databases; finally, the TSV document of string-interactions was visualized by Cytoscape. GO and KEGG Pathway Enrichment Analysis Cluster analysis of biological process of GO was performed with the CluGo2.5.7 plug-in for Cytoscape. To obtain the potential signaling pathway associated with DBD in the treatment of MCC, KEGG analysis was conducted by R 4.0.0 with the Bioconductor program packages clusterProfiler 3.16.1 and dose 3.14.0 installed. Preparation of DBD HQ and DG were mixed in the ratio of 5:1 (dry weight) and immersed in 8 volumes of distilled water (v/m) for 0.5 h, then decocted twice, each time for 1.5 h. This ratio followed the ancient recipe that has been shown to have the best extracting efficiency.[61]21,[62]22 Subsequently, the water-based decoction was combined, filtered, and concentrated to 0.6 g/mL, and stored at −80 °C ahead of the experiment. Animals and Experimental Design All protocols involving animals were approved by the Ethics Committee of Yongchuan Hospital affiliated with the Chongqing Medical University (NO: YCHCQMU2017022521), and the guidelines followed for the welfare of the laboratory animals was GB/T 35,892–2018 Laboratory Animal Guidelines for Ethical Review of Animal Welfare. Sixty male BABL/c mice aged 5–6 weeks (weighing 16±2 g) were purchased from the Laboratory Animal Center of the Chongqing Medical University (SCXK-(yu)2018–0003). All mice were housed in standard husbandry conditions (22 ± 2°C, 60–80% relative humidity, and a 12-hour photoperiod) and given free access to food and water during the course of the experiment. After 1 week of adaptation, 200 ul 5*10^6 CT26 single cell suspension was injected subcutaneously into the right axilla as primary tumor. Five days later, equal volume and density CT26 suspension was injected into the opposite axilla as metastatic tumor.[63]23–25 The mice were then randomly divided into 4 groups (n = 15 per group), primary tumor resected group (R), non-resected primary tumor group (NR), and DBD I group, and DBD II group. Primary tumor resection surgery was performed in all groups except the NR group. Group DBD I received 2 mL/100g of DBD 7 days before surgery; meanwhile, treatment in groups R (2 mL/100g, distilled water), NR (2 mL/100g, distilled water), and DBD II (2 mL/100g, DBD) started 24 hours after the operation. All mice were treated for 14 consecutive days. Tumor volume was measured with vernier caliper every 3 days and calculated using the formula: Volume (mm^3) = 1/2 AB^2, where A and B represented the length and width values, respectively. Animals were sacrificed after the 14th intragastric administration; each tumor mass was removed and weighed. Subsequently, tumor tissue specimens were fixed in 4% paraformaldehyde before embedding them in paraffin; then, sections of 5 μm thickness were cut and stained with hematoxylin and eosin. Histopathological changes in the tumor tissues of groups R, NR, DBD I, and DBD II were evaluated using a light microscope. Western Blot Assay The total protein of metastatic tumor was extracted with RIPA lysis buffer (Beyotime, shanghai, China) containing 1% PMSF. Protein concentration was determined by BCA protein assay reagent (Beyotime, shanghai, China), according to the manufacturer’s instructions. Proteins were separated by SDS-PAGE gels and transferred onto PVDF membranes (Millipore, USA). After blocking with 5% non-fat milk, the membranes were incubated with primary antibodies Bcl2 (1:1000), Bax (1:500), Cas3 (1:1000), and C-cas3 (1:500) at 4 °C overnight; in addition, β-actin (1:5000) was used as a housekeeping gene. Subsequently, the membranes were washed and incubated for 2 hours at room temperature with HRP-conjugated secondary antibodies. Protein bands were detected by ECL Western Blotting Detection Kit (4A Biotech, Beijing, China) and quantified by Image J software. Each experiment was repeated three times. Statistical Analysis Statistical analysis was performed by SPSS Statistics 25 (IBM Corporation, Armonk, NY, USA) using independent-samples t test. Results were expressed as the mean ± standard deviation. P-values of <0.05 were considered indicative of a statistically significant. Results Active Compounds and Related Targets Information of DBD A total of 22 DBD compounds were retrieved from the TCMSP database, using the screening criteria. Compounds such as astragalus polysaccharide, astragaloside, astragaloside III, astragaloside IV, alpha-angelica lactone, and ferulic acid were recognized as active compounds and included in further analysis ([64]Table 1). A total of 596 and 132 targets were predicted in HQ and DG, respectively. Table 1. The Chemical Compounds and ADME Parameters of DBD PubChem CID Compound Name Canonical SMILES OB (%) DL Origin 64971 Mairin CC(=C)C1CCC2(C1C3CCC4C5(CCC(C(C5CCC4(C3(CC2)C)C)(C)C)O)C)C(=O)O 55.38 0.78 HQ 5318869 Jaranol COC1=CC(=C2C(=C1)OC(=C(C2=O)OC)C3=CC=C(C=C3)O)O 50.83 0.29 HQ 73299 Hederagenin CC1(CCC2(CCC3(C(=CCC4C3(CCC5C4(CCC(C5(C)CO)O)C)C)C2C1)C)C(=O)O)C 36.91 0.75 HQ 15976101 24-propylcholesterol CCCC(CCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C)C(C)C 36.23 0.78 HQ 5281654 Isorhamnetin COC1=C(C=CC(=C1)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O 49.6 0.31 HQ 15689655 3,9-di-O-methylnissolin COC1=CC2=C(C=C1)C3C(CO2)C4=C(O3)C(=C(C=C4)OC)OC 53.74 0.48 HQ 15689654 5ʹ-hydroxyiso-muronulatol-2ʹ,5ʹ-di-O-glucoside COC1=C(C=C(C(=C1OC)OC2C(C(C(C(O2)CO)O)O)O)C3CC4=C(C=C(C=C4)O)OC3)OC5C(C (C(C(O5)CO)O)O)O 41.72 0.69 HQ 15689652 7-O-Methylisomucronulatol COC1=CC2=C(CC(CO2)C3=C(C(=C(C=C3)OC)OC)O)C=C1 74.69 0.3 HQ 101679160 9,10-dimethoxypterocarpan-3-O-β-D-glucoside COC1=C(C2=C(C=C1)C3COC4=C(C3O2)C=CC(=C4)OC5C(C(C(C(O5)CO)O)O)O)OC 36.74 0.92 HQ 14077830 Methylnissolin COC1=C(C2=C(C=C1)C3COC4=C(C3O2)C=CC(=C4)O)OC 64.26 0.42 HQ 108213 Bifendate COC1=C2C(=C(C(=C1)C(=O)OC)C3=C4C(=C(C=C3C(=O)OC)OC)OCO4)OCO2 31.1 0.67 HQ 5,280378 formononetin COC1=CC=C(C=C1)C2=COC3=C(C2=O)C=CC(=C3)O 69.67 0.21 HQ 160767 isoflavanone C1C(C(=O)C2=CC=CC=C2O1)C3=CC=CC=C3 109.99 0.3 HQ 5,280448 Calycosin COC1=C(C=C(C=C1)C2=COC3=C(C2=O)C=CC(=C3)O)O 47.75 0.24 HQ 5280863 kaempferol C1=CC(=CC=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O 41.88 0.24 HQ 135398658 Folic acid C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N 68.96 0.71 HQ 10380176 (3R)-3-(2-hydroxy-3,4-dimethoxyphenyl)chroman-7-ol COC1=C(C(=C(C=C1)C2CC3=C(C=C(C=C3)O)OC2)O)OC 67.67 0.26 HQ 15689653 isomucronulatol-7,2ʹ-di-O-glucosiole COC1=C(C(=C(C=C1)C2CC3=C(C=C(C=C3)OC4C(C(C(C(O4)CO)O)O)O)OC2)OC5C(C(C(C (O5)CO)O)O)O)OC 49.28 0.62 HQ 5316760 1,7-Dihydroxy-3,9-dimethoxy pterocarpene COC1=CC(=C2C(=C1)OCC3=C2OC4=CC(=CC(=C34)O)OC)O 39.05 0.48 HQ 5280343 quercetin C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O 46.43 0.28 HQ 2782115 Astragalus polysaccharide C1=CC(=CC=C1C2=CSC(=N2)CCl)[N+](=O)[O-] / / HQ 5488387 Astragaloside COC1=C(C=CC(=C1)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)OC4C(C(C(C(O4)COC5C(C(C(C (O5)CO)O)O)O)O)O)O)O / / HQ 441905 Astragaloside III CC1(C(CCC23C1C(CC4C2(C3)CCC5(C4(CC(C5C6(CCC(O6)C(C)(C)O)C)O)C)C)O)OC7C( C(C(CO7)O)O)OC8C(C(C(C(O8)CO)O)O)O)C 31.83 0.10 HQ 13943297 Astragaloside IV CC1(C(CCC23C1C(CC4C2(C3)CCC5(C4(CC(C5C6(CCC(O6)C(C)(C)O)C)O)C)C)OC7C(C( C(C(O7)CO)O)O)O)OC8C(C(C(CO8)O)O)O)C 22.50 0.15 HQ 222284 beta-sitosterol CCC(CCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C)C(C)C 36.91 0.75 DG 5280794 Stigmasterol CCC(C=CC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C)C(C)C 43.83 0.76 DG 11559 alpha-Angelica lactone CC1=CCC(=O)O1 62.53 0.01 DG 445858 Ferulic acid COC1=C(C=CC(=C1)C=CC(=O)O)O 40.43 0.06 DG [65]Open in a new tab Note: / represents there was no corresponding values of OB and DL. MCCTargets Prediction and the Common Targets A total of 6800 targets related to MCC were obtained from the GeneCards and OMIM databases. A higher relevance score indicated a higher correlation between a gene and MCC; a total of 1751 targets with the relevance score higher than twice the median value were considered candidate therapeutic targets. After comparing the targets of DBD with those of MCC, 61 matched targets were identified ([66]Supplementary Table S1), and a Venn diagram was plotted ([67]Figure 1). The common targets were regarded as the potential therapeutic targets for DBD against MCC. Figure 1. [68]Figure 1 [69]Open in a new tab Venn diagram of common targets in DBD and MCC. Network Visualization To clarify the relationship between active compounds and common targets as well as MCC, a drug-compound-target-disease interaction network with 90 nodes and 458 edges was created by Cytoscape ([70]Figure 2). It contained 26 active compounds and 61 potential targets; at this stage, astragaloside III and alpha-angelica lactone were excluded due to the absence in them of common targets against MCC. The average DC, BC, and CC values were 16.15, 0.01, and 0.42, respectively, for the compounds. There were 13 compounds with DC values higher than the average value, namely, quercetin, hederagenin, jaranol, methylnissolin, formononetin, calycosin, kaempferol, 3.9-di-O-methylnissolin, 24-propylcholesterol, and 7-O-methylisomucronulatol, which belonged to HQ, and beta-sitosterol, ferulic acid, and stigmasterol, which belonged to DG ([71]Table 2). These compounds were considered the main active components of DBD in the treatment of MCC with a high degree value. String platform was employed to explore the interaction among common targets; subsequently, a PPI network was constructed by Cytoscape ([72]Figure 3A). This network comprised 59 nodes (AKR1B10, NQ02 were concealed as disconnected nodes in the network) and 404 edges, with the average degree value of 13.69; R was used to hunt hub genes ([73]Figure 3B). The greater connectivity between the nodes, the more important the nodes in this network. JUN, PTSG2, EGFR, ESR1, and CASP3 were the top five target genes in the PPI network and the main targets of DBD ([74]Table 3). Figure 2. [75]Figure 2 [76]Open in a new tab DBD-compound-target-MCC network. All nodes were visualized in degree value, the larger the node, the darker the color and the higher the degree value. In this network, the red diamonds represent candidate targets of DBD against MCC, the orange and claybank octagons represent active compounds in HQ and DG, the green ellipse represent disease, while the remaining golden squares represent HQ and DG. Table 2. The Topological Parameter Analysis of Top 13 Compounds in DBD Number Compound Degree Centrality Betweenness Centrality Closeness Centrality 1 Quercetin 49 0.12 0.57 2 Beta-sitosterol 33 0.06 0.49 3 Ferulic acid 31 0.06 0.49 4 Stigmasterol 28 0.04 0.47 5 Hederagenin 27 0.03 0.46 6 Jaranol 26 0.03 0.46 7 Methylnissolin 25 0.03 0.46 8 Formononetin 25 0.02 0.45 9 Calycosin 24 0.02 0.45 10 Kaempferol 23 0.03 0.45 11 3,9-di-O-methylnissolin 19 0.02 0.43 12 24-propylcholesterol 19 0.02 0.43 13 7-O-methylisomucronulatol 17 0.01 0.42 [77]Open in a new tab Figure 3. [78]Figure 3 [79]Open in a new tab The construction of protein-protein interaction network. (A) Protein-Protein interaction network. Edges represent protein-protein interactions, edge thickness indicates the strength of data support, the larger the node, the higher the degree value. Golden circles represent the targets that interact with CASP3. (B) Common Targets-bar plot diagram. X-axis represents the number of nodes connected and Y-axis represents the target gene symbol. Table 3. Parameters of the Top 30 Genes in the PPI Network Number Gene Degree Betweenness Centrality Closeness Centrality Connected Nodes 1 PTGS2 35 0.10 0.72 35 2 JUN 35 0.06 0.72 35 3 EGFR 34 0.08 0.71 34 4 ESR1 33 0.07 0.70 33 5 CASP3 30 0.05 0.67 30 6 STAT3 29 0.04 0.66 29 7 MMP9 26 0.05 0.64 26 8 RELA 25 0.03 0.63 25 9 PPARG 25 0.05 0.64 25 10 AR 24 0.05 0.62 24 11 AHR 23 0.02 0.62 23 12 PGR 22 0.03 0.61 22 13 MMP2 21 0.01 0.60 21 14 CYP1A1 19 0.03 0.59 19 15 CYP19A1 18 0.02 0.59 18 16 NCOA1 17 0.02 0.57 17 17 CASP8 16 0.01 0.57 16 18 NCOA2 16 0.02 0.56 16 19 NOS2 15 0.02 0.55 15 20 APP 15 0.05 0.57 15 21 PARP1 15 0.01 0.55 15 22 ESR2 15 0.01 0.56 15 23 ABCB1 14 0.02 0.55 14 24 MET 13 0.00 0.54 13 25 CASP9 13 0.00 0.54 13 26 PLAU 12 0.01 0.54 12 27 MMP1 12 0.00 0.55 12 28 PPARA 12 0.01 0.53 12 29 RXRA 12 0.01 0.51 12 30 TLR9 11 0.00 0.52 11 [80]Open in a new tab GO and KEGG Enrichment Analysis To explore the biological processes of GO regulated by DBD, cluster analysis of common targets was performed through CluGo for the human species, P≤0.05, and the Kappa score threshold value of 0.4. A total of 42 biological processes were enriched ([81]Figure 4A) and formed 15 clusters ([82]Figure 4B). Terms with the same color belonged to the same cluster: nuclear receptor activity, steroid hormone receptor activity, myeloid leukocyte differentiation, positive regulation of bone resorption, icosanoid metabolic process, regulation of intrinsic apoptotic signaling pathway, positive regulation of smooth muscle cell proliferation, placenta development, positive regulation of neuron death, response to molecules of bacterial origin, cell death in response to oxidative stress, diterpenoid metabolic process, activation of cysteine-type endopeptidase activity involved in the apoptotic process, positive regulation of NIK/NF-kappa B signaling, and regulation of cardiac muscle hypertrophy were the leading terms, based on the highest significance value in each cluster. The KEGG pathway enrichment analysis was performed by R with FDR of ≤0.05 ([83]Figure 5). Among the top 30 signaling pathways, Apoptosis-multiple species (hsa04215), Apoptosis (hsa04210) and Colorectal cancer (hsa05210) were involved in regulating MCC progression. These findings suggest that DBD likely inhibited MCC by regulating the biological processes and pathways related to apoptosis; the subsequent in vivo experiment helped verify this hypothesis. Figure 4. [84]Figure 4 [85]Open in a new tab GO enrichment analysis. Different colors represent different clusters. (A) Terms of enriched biological processes on common targets. X-axis represents the percentage of the target genes versus the background genes in each term, Y-axis represents the name of biological processes, the red **Represents the number of enriched target genes. (B) Percentage of each cluster. The name of each term represents the leading term based on the highest significance value in each cluster. Figure 5. [86]Figure 5 [87]Open in a new tab KEGG pathway enrichment dot-plot diagram. The top 30 signaling pathways regulated by DBD. X-axis represents the ratio of enriched target genes/background genes. Y-axis represents the term of enriched pathways. The sizes of the dots indicate the number of target genes in a certain pathway, and the colors of the dots reflect the different values of p.adjust. DBD Alleviated MCC Progression in Mice Palpable tumors were observed on day 5 after tumor cell inoculation. The tumor growth rate decreased successively in groups R, NR, DBD I, and DBD II ([88]Figure 6A). After 2 weeks of treatment with postoperative administration of DBD, reduction in tumor weight of 74.3% was observed in the DBD II group, compared to the R group (p < 0.0001), and non-excision of primary tumor caused a reduction in tumor weight of 25.1% compared with the R group (p<0.001). The mean values of tumor weight were 2.41 ± 0.30 g, 1.81 ± 0.17 g, 1.34 ± 0.15 g, and 0.62 ± 0.13 g for groups R, NR, DBD I, and DBD II respectively ([89]Figure 6B and [90]Supplementary Figure S1). Neoplastic cells exhibited increased nucleo-cytoplasmic ratio, nuclear atypia rate, and hyperchromatic nuclei count in group R. Treatment with DBD reduced the nucleo-cytoplasmic ratio as well as the volume of neoplastic cells, increasing the rate of necrosis ([91]Figure 7). These findings indicate that DBD may inhibit MCC progression. Figure 6. [92]Figure 6 [93]Open in a new tab DBD inhibited the growth of metastatic tumor. (A) Growth curve of metastatic tumor. (B) Metastatic tumor weight. All data was presented as mean ± standard deviation, ***p<0.001, ****p<0.0001. Figure 7. [94]Figure 7 [95]Open in a new tab Histopathological examination. HE staining of metastatic tumor. Representative image for HE staining of tumor sections from groups R, NR, DBD I and DBD II at 400x magnification power. Expression of Bax, Bcl2, Cas3, and C-Cas3 in Metastatic Tumor Western blot analysis indicated that the expression of Bax, Cas3, and C-cas3 was up-regulated in the DBD I/II groups compared to that in the R group; moreover, the expression of these proteins in the DBD II group was markedly up-regulated compared to that in the R group (p<0.001, p<0.01). Meanwhile, it was down-regulated in the R group compared to the NR group (p<0.05, p<0.01) ([96]Figure 8). In contrast, the expression of Bcl2 was down-regulated in the DBD I/II groups compared to that in the R group; moreover, in the DBD II group, it was significantly down-regulated compared to that in the R group (p<0.0001). Finally, the expression of Bcl2 in the R group was up-regulated compared to that in the NR group (p<0.01) ([97]Figure 8C). In addition, we calculated the ratio of Bax/Bcl2 in four groups; in the DBD I/II groups, it increased more than it did in the R group, while in the R group, it was lower than in the DBD II and NR groups ([98]Figure 8D). These findings indicate that DBD may induce metastatic tumor apoptosis by up-regulating Bax, Cas3, and C-cas3, and down-regulating Bcl2 protein expression. Figure 8. [99]Figure 8 [100]Open in a new tab DBD inhibited the growth of metastatic tumor through inducing cell apoptosis. (A) The effect of DBD on metastatic tumor was analyzed by Western blot. Figures (B and C, E and F) showed the expression of Bax, Bcl2, Cas3 and C-cas3 in metastatic tumor among R, NR, DBD I and DBD II groups, with β-actin as internal control. (D) Western blot analysis showed the ratio of Bax/Bcl2 in Metastatic tumor among groups R, NR, DBD I and DBD II. All data was presented as mean ± standard deviation. (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001). Discussion Clinical practice and many mice models have proven that surgical removal of the primary tumor facilitates the development of metastases.[101]5,[102]8 We hypothesize that DBD could inhibit metastatic colon cancer progress after the primary tumor removal. In the present study, the candidate DBD compounds and targets against MCC were predicted using network pharmacology, which yielded 28 compounds and 61 targets. The present findings indicated that the main DBD compounds involved in the treatment of MCC were quercetin, hederagenin, jaranol, methylnissolin, formononetin, calycosin, kaempferol, 3.9-di-O-methylnissolin, 24-propylcholesterol, 7-O-methylisomucronulatol, beta-sitosterol, ferulic acid, and stigmasterol. Previous pharmacological research has shown that a combination of quercetin and 2-methoxyestradiol enhanced the inhibition of human prostate cancer LNCaP and PC-3 cells xenograft tumor growth.[103]26 A previous in vitro experiment indicated that hederagenin induced apoptosis in breast cancer cells by regulating the mitochondrial apoptosis pathway.[104]27 Kumatakenin (jaranol) induced caspase-dependent apoptosis in human ovarian cancer cells by increasing the expression of caspase-3, −8, and −9.[105]28 Meanwhile, formononetin inhibited the proliferation and metastasis of ovarian cancer in vitro;[106]29 finally, calycosin induced apoptosis of cervical cancer and adenocarcinoma.[107]30,[108]31 In addition, a separate study has shown that beta-sitosterol and gemcitabine exhibit synergistic anti-pancreatic cancer activity by modulating apoptosis and inhibiting epithelial–mesenchymal transition, while ferulic acid inhibited the proliferation and migration of human lung cancer cells in vitro.[109]32 These compounds have been shown to exert pro-apoptosis activity in many cancer cell types. Presently, the PPI network showed that Cas3 was among the hub genes linked to 30 targets with a high degree value, closely associated with apoptosis. Findings from the GO and KEGG enrichment analyses indicated that apoptosis played a major role in the biological processes and signaling pathways of MCC. Inadequacy and induction of apoptosis are among the hallmarks of cancer-associated and anti-tumor mechanisms, respectively.[110]33 The process of intrinsic/mitochondrial apoptosis involves two protein families, among which the Bcl2 family regulates the mitochondrial membrane permeability, while the caspase family is the “executor” of apoptosis. The apoptotic trigger conveys signals between the “regulators” and “executors” in a way that is controlled by counter-balancing the expression of pro- and antiapoptotic members of the Bcl2 family of regulatory proteins.[111]34 Anti-apoptotic protein Bcl2 embedded in the mitochondrial outer membrane inhibits cytochrome C release; meanwhile, pro-apoptotic protein Bax belonging to Bcl2 family and embedded in the cytoplasm is transported into the mitochondria after receiving cell death-related signals and promotes the release of cytochrome C, which activates caspase cascade responsible for apoptosis execution. The up-regulation of Bcl2 expression as a barrier to apoptosis has been described in several types of solid tumors.[112]35 An in vitro experiment revealed that MiR-136 triggers apoptosis in human gastric cancer cells by down-regulating Bcl2 expression.[113]36 Bcl2-inhibitor venetoclax prolonged progression free survival and increased sensitivity to chemoradiotherapy in patients with ER- and Bcl2-positive metastatic breast cancer.[114]37 Furthermore, the ratio of Bax/Bcl2 serves as a marker of cell susceptibility to apoptosis.[115]38 A previous clinical study has revealed that a higher level of Bax prolonged the median disease-free survival and increased chemotherapy sensitivity among patients with ovarian cancer.[116]39 A notable feature of apoptosis is that it exerts its effects mainly through the activity of a type of serine protease known as caspase,[117]40 which cleave and activate each other. The caspase protein family subdivides into sub-families based upon function, including initiator (caspases 2, 8, 9, and 10) and effector/executioner (caspases 3, 6, and 7) groups; the latter group exerts apoptotic effects.[118]41 Cas3 is generally regarded as the major apoptotic mediator and a positive marker of an effective therapeutic strategy in cancer. The present findings suggest that DBD up-regulates the expression of Bax, Cas3, C-cas3, and increases the ratio of Bax/Bcl2, while it down-regulates the expression of Bcl2; these findings indicate that DBD may inhibit the progress of MCC by inducing cell apoptosis. Conclusion This study systematically identified the compounds and mechanisms of action involved in DBD in the treatment of MCC using network pharmacology analysis and experimental validation. The present findings support the theory that surgical removal of the primary tumor promotes metastatic tumor growth; In contrast, administration of DBD in the perioperative period could inhibit the progress of MCC after primary tumor resection; its postoperative administration achieved effects superior to those achieved by its preoperative administration. This suggests that postoperative application of DBD may achieve better overall effect on metastatic foci in colon cancer patients after primary tumor resection. In addition, the present findings provide some evidence for the application of tonic therapy in tumor treatment at the perioperative period. The limitation of our study is that the candidate compounds of DBD in the treatment of MCC was based on network pharmacology prediction only, more extensive experiments are needed to provide experimental evidence in the future. Acknowledgments